These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 28858541)

  • 41. Predictive role of PI-RADSv2 and ADC parameters in differentiating Gleason pattern 3 + 4 and 4 + 3 prostate cancer.
    Alessandrino F; Taghipour M; Hassanzadeh E; Ziaei A; Vangel M; Fedorov A; Tempany CM; Fennessy FM
    Abdom Radiol (NY); 2019 Jan; 44(1):279-285. PubMed ID: 30066169
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantitative Analysis of Diffusion Weighted Imaging May Improve Risk Stratification of Prostatic Transition Zone Lesions.
    Engel H; Oerther B; Reisert M; Kellner E; Sigle A; Gratzke C; Bronsert P; Krauss T; Bamberg F; Benndorf M
    In Vivo; 2022; 36(5):2323-2331. PubMed ID: 36099133
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnostic Performance of Prostate-specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-analysis.
    Wang S; Kozarek J; Russell R; Drescher M; Khan A; Kundra V; Barry KH; Naslund M; Siddiqui MM
    Eur Urol Oncol; 2024 Apr; 7(2):189-203. PubMed ID: 37640584
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reduction of false positives using zone-specific prostate-specific antigen density for prostate MRI-based biopsy decision strategies.
    Hamm CA; Baumgärtner GL; Padhani AR; Froböse KP; Dräger F; Beetz NL; Savic LJ; Posch H; Lenk J; Schallenberg S; Maxeiner A; Cash H; Günzel K; Hamm B; Asbach P; Penzkofer T
    Eur Radiol; 2024 Oct; 34(10):6229-6240. PubMed ID: 38538841
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of PI-RADS 2, ADC histogram-derived parameters, and their combination for the diagnosis of peripheral zone prostate cancer.
    Lin WC; Westphalen AC; Silva GE; Chodraui Filho S; Reis RB; Muglia VF
    Abdom Radiol (NY); 2016 Nov; 41(11):2209-2217. PubMed ID: 27364781
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
    Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
    Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
    [TBL] [Abstract][Full Text] [Related]  

  • 47. How Often is the Dynamic Contrast Enhanced Score Needed in PI-RADS Version 2?
    Roh AT; Fan RE; Sonn GA; Vasanawala SS; Ghanouni P; Loening AM
    Curr Probl Diagn Radiol; 2020; 49(3):173-176. PubMed ID: 31126664
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The value of DISCO and MUSE-DWI combined with prostate specific antigen density in the diagnosis and risk stratification of prostate cancer].
    Chen ZQ; Zhang D; Wang Z; Song N; Ma AL; Zhang SR; Cai L
    Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1461-1468. PubMed ID: 37198108
    [No Abstract]   [Full Text] [Related]  

  • 49. The Negative Predictive Value of a PI-RADS Version 2 Score of 1 on Prostate MRI and the Factors Associated With a False-Negative MRI Study.
    Ma HY; Ahmed FS; Luk L; Martina LAP; Wenske S; Shaish H
    AJR Am J Roentgenol; 2020 Sep; 215(3):667-672. PubMed ID: 32755155
    [No Abstract]   [Full Text] [Related]  

  • 50. Interreader Agreement of Prostate Imaging Reporting and Data System Version 2 Using an In-Bore MRI-Guided Prostate Biopsy Cohort: A Single Institution's Initial Experience.
    Glazer DI; Mayo-Smith WW; Sainani NI; Sadow CA; Vangel MG; Tempany CM; Dunne RM
    AJR Am J Roentgenol; 2017 Sep; 209(3):W145-W151. PubMed ID: 28657843
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
    Niu XK; Li J; Das SK; Xiong Y; Yang CB; Peng T
    BMC Med Imaging; 2017 Feb; 17(1):11. PubMed ID: 28143433
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluating the performance of PI-RADS v2 in the non-academic setting.
    Jordan EJ; Fiske C; Zagoria RJ; Westphalen AC
    Abdom Radiol (NY); 2017 Nov; 42(11):2725-2731. PubMed ID: 28451763
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The clinical decision-making value of prostate specific antigen and its derived indicators in prostate imaging reporting and data system version 2 3 lesions].
    Yang S; Zhang YY; Zhao WL; Wei CG; Chen T; Li MJ; Tan SX; Shen JK
    Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(13):997-1001. PubMed ID: 32294856
    [No Abstract]   [Full Text] [Related]  

  • 54. Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison.
    Tosun M; Uslu H
    Clin Imaging; 2021 Oct; 78():98-103. PubMed ID: 33773450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of PI-RADS Version 2 for Prediction of Upgrading in Biopsy-Proven Prostate Cancer With Gleason Score 6.
    Song W; Bang SH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Kim CK; Lee HM
    Clin Genitourin Cancer; 2018 Aug; 16(4):281-287. PubMed ID: 29550198
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference.
    Vargas HA; Hötker AM; Goldman DA; Moskowitz CS; Gondo T; Matsumoto K; Ehdaie B; Woo S; Fine SW; Reuter VE; Sala E; Hricak H
    Eur Radiol; 2016 Jun; 26(6):1606-12. PubMed ID: 26396111
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of clinically signifi cant prostate cancer with PIRADS v2 scores, PSA density, and ADC values in regions with and without mpMRI visible lesions.
    Westphalen AC; Fazel F; Nguyen H; Cabarrus M; Hanley-Knutson K; Shinohara K; Carroll PR
    Int Braz J Urol; 2019; 45(4):713-723. PubMed ID: 31136112
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
    Druskin SC; Tosoian JJ; Young A; Collica S; Srivastava A; Ghabili K; Macura KJ; Carter HB; Partin AW; Sokoll LJ; Ross AE; Pavlovich CP
    BJU Int; 2018 Apr; 121(4):619-626. PubMed ID: 29232037
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Real-time MRI/US fusion-guided biopsy improves detection rates of prostate cancer in pre-biopsied patients].
    Maxeiner A; Fischer T; Stephan C; Cash H; Slowinski T; Kilic E; Durmus T
    Aktuelle Urol; 2014 May; 45(3):197-203. PubMed ID: 24902069
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer.
    Deniffel D; Healy GM; Dong X; Ghai S; Salinas-Miranda E; Fleshner N; Hamilton R; Kulkarni G; Toi A; van der Kwast T; Zlotta A; Finelli A; Perlis N; Haider MA
    Radiology; 2021 Aug; 300(2):369-379. PubMed ID: 34032510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.